US FDA•United StatesCRL•Complete Response Letter

Complete Response Letter NDA 505b1 215644 (Jun 25, 2025)

Issued June 25, 2025

Issued

June 25, 2025

Application

NDA 505b1 • 215644

Review center

CDER

Stage

Final Decision

Letter type

Complete Response Letter

Response due June 25, 2026Requires resubmission addressing deficiencies.

Summary

This section outlines requirements for responding to deficiencies identified during inspections and for providing a comprehensive safety update for New Drug Application (NDA) 215644. It details specific content and formatting for the safety update, including new data integration, comparative tables, and narrative summaries for adverse events and trial discontinuations.

Key points

Include the date(s) of the facility’s response(s) to the FDA Form 483 in the complete response.
Refer to Compliance Program CP 7356.002 for guidance on post-inspection activities specific to CGMP compliance evaluation.
Include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b) when responding to deficiencies.
The safety update must include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.
Describe in detail any significant changes or findings in the safety profile.
Incorporate new safety data when assembling sections describing discontinuations due to adverse events, serious adverse events, and common adverse events.
Present new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission.
Present tabulations of the new safety data combined with the original application data.

Cited reasons

Comprehensive Safety Update Required
Separate Adverse Event Tables for Other Indications
Submission of Case Report Forms and Narrative Summaries
Resolution of CGMP and PAI Inspection Deficiencies
The FDA issued a Complete Response Letter for NDA 215644, primarily citing significant deficiencies in the clinical safety data presentation and reporting. This includes the need for a comprehensive safety update, separate adverse event tables for non-proposed indications, and submission of case report forms and narrative summaries for deaths and serious adverse events. Additionally, resolution of facility inspection (CGMP/PAI) deficiencies is required.

Recommended actions

Include the date(s) of the facility’s response(s) to the FDA Form 483 in the complete response.
Refer to Compliance Program CP 7356.002 for guidance on post-inspection activities specific to CGMP compliance evaluation.
Include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b) when responding to deficiencies.
The safety update must include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.
Describe in detail any significant changes or findings in the safety profile.
Incorporate new safety data when assembling sections describing discontinuations due to adverse events, serious adverse events, and common adverse events.
Present new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission.
Present tabulations of the new safety data combined with the original application data.

Deficiency summary

The FDA issued a Complete Response Letter for NDA 215644, primarily citing significant deficiencies in the clinical safety data presentation and reporting. This includes the need for a comprehensive safety update, separate adverse event tables for non-proposed indications, and submission of case report forms and narrative summaries for deaths and serious adverse events. Additionally, resolution of facility inspection (CGMP/PAI) deficiencies is required.

Findings

Comprehensive Safety Update Required

Severity: major

A comprehensive safety update is required as described at 21 CFR 314.50(d)(5)(vi)(b). This update must include data from all nonclinical and clinical studies/trials of the drug, regardless of indication, dosage form, or dose level, and detail any significant changes or findings in the safety profile.

Recommended response: Prepare a comprehensive safety update report, ensuring all nonclinical and clinical data are included and significant changes in the safety profile are clearly described, adhering strictly to 21 CFR 314.50(d)(5)(vi)(b).

Cited: 21 CFR 314.50(d)(5)(vi)(b)

Separate Adverse Event Tables for Other Indications

Severity: major

For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.

Recommended response: Generate separate adverse event frequency tables for all clinical trials related to indications other than the proposed one, ensuring clear presentation and statistical rigor.

Submission of Case Report Forms and Narrative Summaries

Severity: major

Provide case report forms and narrative summaries for each subject who died during a clinical trial or who did not complete a trial due to an adverse event. Additionally, provide narrative summaries for all serious adverse events.

Recommended response: Compile and submit all requested case report forms and detailed narrative summaries for subjects experiencing death or trial discontinuation due to adverse events, as well as for all serious adverse events.

Resolution of CGMP and PAI Inspection Deficiencies

Severity: major

Address facility inspection deficiencies, including providing date(s) of the facility’s response(s) to FDA Form 483. FDA may require CGMP reinspection and/or additional pre-approval inspection (PAI) to confirm satisfactory resolution before approval.

Recommended response: Submit responses to FDA Form 483 findings, prepare for potential CGMP reinspection and/or PAI, and ensure all manufacturing and quality system deficiencies are fully resolved.

Regulatory context

Submission stage: final decision
Regulatory pathway: NDA

Impact

Impact score: 0.75
Estimated delay: 270 days
Estimated rework cost: $0
Subsequent action: resubmission

Strategic insights

The primary themes are inadequate clinical safety data reporting and presentation, particularly concerning adverse events and serious outcomes, requiring a comprehensive safety update. There are also unresolved manufacturing and quality system deficiencies identified during facility inspections.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 25%

Document viewer

Read the FDA letter and send context to the co-pilot at any time.

Loading document viewer…